texas oncology more breakthroughs. more victories
I am a: Patient | Caregiver | Refering Physician
Some of our cancer centers may have important notifications found on the location page. View More Important Notifications x

Insights Into the Role of Immune Checkpoint Inhibitors in Colorectal Cancer

Publication: ASCO Dayli News

Immune checkpoint inhibitor therapy has revolutionized the management of many cancers, including colorectal cancer (CRC) with microsatellite instability (MSI). Unfortunately, for the majority of CRCs, which are microsatellite stable (MSS), checkpoint inhibitors alone are ineffective. Herein, we review the impact of checkpoint inhibitors in MSI-high (MSI-H) CRC, mechanisms of resistance to checkpoint inhibitors in MSS CRC, and signals for the future from the recent REGONIVO trial. The Table highlights relevant immunotherapy-related clinical trials done to date in CRC.

Read the full story at ASCO Dayli News.

About Texas Oncology

With more than 530 physicians and 280 locations, Texas Oncology is an independent private practice that sees more than 71,000 new cancer patients each year. Founded in 1986, Texas Oncology provides comprehensive, multi-disciplinary care, and includes Texas Center for Proton Therapy, Texas Breast Specialists, Texas Colon & Rectal Specialists, Texas Oncology Surgical Specialists, Texas Urology Specialists and Texas Infusion and Imaging Center. Texas Oncology’s robust community-based clinical trials and research program has contributed to the development of more than 100 FDA-approved cancer therapies. Learn more at TexasOncology.com.

Related Physicians